Hims & Hers Health Inc HIMS shares are trading higher on Tuesday as investors continue to react to a new chief medical ...

Hims is rolling out a new Weight Loss Membership that lets you get started for $39 for the first month. You’ll get 24/7 ...

Hims has delivered impressive growth, attracting millions of customers and expanding into new healthcare categories. But ...

Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, the parent company of Juniper, advancing its position ...

Learn more Leerink maintained a 'Market Perform' rating and a $25 price target, implying a 10% downside from current levels.

Hims is dealing with margin compression. While Hims management raised its revenue outlook for the year, it significantly lowered its adjusted EBITDA guidance. It now expects reven ...

Hims & Hers continues growing rapidly, but shrinking margins and rising costs are beginning to test the company's long-term profitability story.

Hims & Hers stock (NYSE: HIMS) increased by 16% yesterday following its announcement about expanding into the treatment of menopause and perimenopause—a strategic shift indicating that the company is ...

Is HIMS a good stock to buy? We came across a bearish thesis on Hims & Hers Health, Inc. on Valueinvestorsclub.com by Pridwen ...

Hims & Hers Health missed Wall Street estimates for first-quarter revenue and posted a surprise loss on Monday, ​as the ...

CHONGQING, CHINA - MAY 04: In this photo illustration, the logo of Hims & Hers Health, Inc. is displayed on a smartphone screen, with the company's stock market performance and candlestick chart ...

Hims offers convenient, discreet prescription hair loss treatments for men. Learn if it's right for you and what to expect.